anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses tyrosinase inhibitor microemulsion as well as a preparation method and an application thereof, and belongs to the technical fields of foods, medicines and cosmetics. The microemulsion contains a matrix, a tyrosinase inhibitor norartocarpetin and water, wherein the matrix comprises 40%-60% of surface active agent, 20%-45% of cosurfactant and 5%-20% of oil phase; and the microemulsion is prepared by adding raw components according to a certain ratio. The tyrosinase inhibitor microemulsion can be used for overcoming the defects that the solubility of the natural tyrosinase inhibitor norartocarpetin in water is extremely low. The method provided by the invention is simple to operate and can be used for the spontaneous formation of the microemulsion. Nanoscale microemulsion can be formed by using water or an aqueous solution for diluting the tyrosinase inhibitor microemulsion. The obtained microemulsion can be used for effectively resisting enzymatic browning of fruits and vegetables, and preparing whitening cosmetics and other medicines for preventing and treating human hyperpigmentation diseases and melanomas (caused by excessive melanin) needing to inhibit the activity of tyrosinase.
BACKGROUND: PSMA PET/CT is a predictive and prognostic biomarker for determining response to [177Lu]Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer (mCRPC). Thresholds defined to date may not be generalizable to newer image reconstruction algorithms. Bayesian penalized likelihood (BPL) reconstruction algorithm is a novel reconstruction algorithm that may improve contrast whilst preventing introduction of image noise. The aim of this study is to compare the quantitative parameters obtained using BPL and the Ordered Subset Expectation Maximization (OSEM) reconstruction algorithms.
METHODS: Fifty consecutive patients with mCRPC who underwent [68Ga]Ga-PSMA-11 PET/CT using OSEM reconstruction to assess suitability for [177Lu]Lu-PSMA-617 therapy were selected. BPL algorithm was then used retrospectively to reconstruct the same PET raw data. Quantitative and volumetric measurements such as tumour standardised uptake value (SUV)max, SUVmean and Molecular Tumour Volume (MTV-PSMA) were calculated on both reconstruction methods. Results were compared (Bland-Altman, Pearson correlation coefficient) including subgroups with low and high-volume disease burdens (MTV-PSMA cut-off 40 mL).
RESULTS: The SUVmax and SUVmean were higher, and MTV-PSMA was lower in the BPL reconstructed images compared to the OSEM group, with a mean difference of 8.4 (17.5%), 0.7 (8.2%) and - 21.5 mL (-3.4%), respectively. There was a strong correlation between the calculated SUVmax, SUVmean, and MTV-PSMA values in the OSEM and BPL reconstructed images (Pearson r values of 0.98, 0.99, and 1.0, respectively). No patients were reclassified from low to high volume disease or vice versa when switching from OSEM to BPL reconstruction.
CONCLUSIONS: [68Ga]Ga-PSMA-11 PET/CT quantitative and volumetric parameters produced by BPL and OSEM reconstruction methods are strongly correlated. Differences are proportional and small for SUVmean, which is used as a predictive biomarker. Our study suggests that both reconstruction methods are acceptable without clinical impact on quantitative or volumetric findings. For longitudinal comparison, committing to the same reconstruction method would be preferred to ensure consistency.
PURPOSE:To provide the subject safe cosmetic stable for a long period of time, excellent in the absorbability for the active ingredient and the sustainability of its effect. CONSTITUTION:The objective cosmetic formulated with a liposome with the constituent being dialkyl-type phospholipid and/or its derivative of the formula (R<1>-R<3> are each H or lower alkyl), a form of old bacterial lipids, capable of mass synthesis and industrial production (e.g. 1,2-di-O-phytanyl-glycero- phosphocholine; where, R<1>=R<2>=R<3>=CH3). This liposome is excellent in both thermal stability and preservability compared with conventional liposomes consisting of diacyl-type phospholipids having been generally used, being also stable to the change in pH and osmotic pressure and to physiologically active substances, etc. Besides, this liposome, like conventional ones, has percutaneous absorption effect and such effect's sustainability, and the phospholipid as the constituent is also high in biocompatibility. For the present liposome, any substance having effects as cosmetics, such as humectant effect, skin whitening effect, aging-preventive effect, dermal cell-activating effect, or ultraviolet light absorption or screening effect, can be used.
Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L-DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L-DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L-DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L-DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L-DOPA-treated 5xFAD mice did not exhibit changes in tau hyperphosphorylation or tau kinase levels. These data suggest that L-DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.
CBT is a behavioral intervention that consists of 12 weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
The invention aims at providing a lansoprazole lyophilized medicine composition used for injection. According to the invention, lansoprazole is dissolved in a solution of sodium hydroxide and mannitol; the obtained solution is lyophilized, such that the medicine composition is obtained. In the medicine composition, a weight ratio of lansoprazole:mannitol:sodium hydroxide is 2-8.5:2-8.5:1, and preferably 6:6:1. The medicine composition is advantaged in simple formula and small amount of auxiliary materials. Therefore, side effects caused by excess dosages of auxiliary materials are overcome; a lyophilization time is greatly reduced, such that unnecessary energy consumption is saved. Therefore, the lansoprazole medicine composition has certain competitive strength in markets.
Standard of Care and Blood Collection for Baseline Circulating Tumor Cells (CTCs) Numeration and H2AX Assay. Participants who have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Week 1 starts with the first Radium 223 treatment and week 24 ends 4 weeks after the last or sixth Radium 223 treatment. The circulating prostate cancer cell analysis will be performed within 24 hours of blood draw. Any unused blood samples for circulating prostate cancer cell analysis will be disposed per lab protocol.
Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c \>8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
Ischemic colitis is a disease in which local tissue in the intestinal wall dies to varying degrees due to insufficient blood supply to the colon. Risk factors include cardiovascular disease, diabetes, chronic kidney disease, chronic obstructive pulmonary disease, etc. Typical clinical manifestations of the disease are abdominal pain and hematochezia. The most common locations are the watershed areas of splenic flexure and rectosigmoid junction. The lesions are segmental and clearly demarcated from normal mucosa under endoscopy. The digestive tract is a common extra-pulmonary organ affected by the novel coronavirus, which can be directly damaged by the virus or indirectly caused by virus-mediated inflammation and hypercoagulability. The corona virus disease 2019 (COVID-19) associated intestinal injury can be characterized by malabsorption, malnutrition, intestinal flora shift, etc. CT can show intestinal ischemia, intestinal wall thickening, intestinal wall cystoid gas, intestinal obstruction, ascites, intussusception and other signs. In this study, we reported a case of ischemic colitis in a moderate COVID-19 patient. The affected area was atypical and the endoscope showed diffuse lesions from the cecum to the rectosigmoid junction. No signs of intestinal ischemia were found on imaging and clear thrombosis in small interstitial vessels was found in pathological tissue. Combined with the fact that the patient had no special risk factors in his past history, the laboratory tests indicated elevated ferritin and D-dimer, while the autoantibodies and fecal etiology results were negative, we speculated that the hypercoagulability caused by novel coronavirus infection was involved in the occurrence and development of the disease in this patient. After prolonged infusion support and prophylactic anti-infection therapy, the patient slowly resumed diet and eventually went into remission. Finally, we hoped to attract clinical attention with the help of this case of moderate COVID-19 complicated with ischemic colitis which had a wide range of lesions and a slow reco-very. For patients with abdominal pain and blood in the stool after being diagnosed as COVID-19, even if they are not severe COVID-19, they should be alert to the possibility of ischemic colitis, so as not to be mistaken for gastrointestinal reactions related to COVID-19.
Patients receive gadolinium IV on day 1 and ferumoxytol non-stoichiometric magnetite IV on day 2. Patients undergo anatomical MRI sequences with 3T or 7T at baseline and on days 1-3. Patients also undergo DSC MRI and DCE MRI on days 1-2. Day 1 and day 2 imaging sessions may be separated by up to 7 days.
Participants receive 6 mg MK-1167 oral loading doses QD Days 1 to 7, followed by 3 mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also receive 10 mg oral Donepezil on Days -3 to 21.
<P>PROBLEM TO BE SOLVED: To provide a humectant cosmetic without having sticky feeling and excellent in humectant property.  <P>SOLUTION: This cosmetic composition without having the stickiness of the humectant contains a poly-γ-L-glutamic acid and/or its salt and a humectant. The humectant may be a hydrophilic humectant and/or a lipophilic humectant. Further, the cosmetic composition may contain an ultraviolet light absorbent and/or an anti-bacterial agent. The cosmetic composition can be utilized as a cosmetic, quasi-drug, medical supply, hygienic material or medicine.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Postoperative delirium (POD) can cause poor patient outcomes in older adults who undergo surgery. In this study, we tested plasma extracellular vesicle (EV) miRNAs obtained before the delirium event to find predictive POD biomarkers after spine surgery. We recruited patients who are more than 70 years old and have undergone spine surgery. Finally, POD patients (n = 31) were included, with no-POD patients matched in age, sex, medical history, and type of surgery (n = 31). Peripheral blood was collected from patients in the operating room after the operation was completed. EVs were isolated from plasma, and the 798 miRNA expression level from EVs was measured using a NanoString platform. Sixty-two patients were included in the study; all were Korean, 67.7% were females, and the median age was 75 years. Preoperative medical history was not statistically different between no-POD and POD patients except for hypertension and the American Society of Anesthesiologists physical status. From the miRNA profiling, we identified 142 significantly differentially expressed miRNAs in POD patients compared with no-POD patients, which are associated with psychological/neurological disorders. The top 10 differentially expressed miRNAs including miR-548ar-5p and miR-627-5p were all upregulated in POD patients and the results were validated using qRT-PCR from the independent sets of samples (n = 96). We demonstrated the potential of plasma EV-miRNAs as predictive biomarkers to identify the risk group of POD after spine surgery. It also provides opportunities for future studies investigating the role of EV-miRNAs in delirium pathology.
Recurrent acute pancreatitis (RAP) is defined as 2 or more distinct episodes of acute pancreatitis (AP) with complete resolution between each episode, and absence of irreversible structural and functional changes in pancreas. RAP has an estimated annual incidence of 8-10 per 100,000 and the recurrence rate is as high as 10-30% in AP patients. At present, biliary, alcoholic and hypertriglyceridemia are common causes of RAP. There are also a variety of causes that may contribute to recurrent episodes of AP, such as gene mutations, pancreas divisum, ampullary neoplasms and sphincter of Oddi dysfunction. About 80% of RAP patients can be identified through routine clinical investigations (include proper history, physical examination, imaging examination); however, the etiology in up to 20% of cases still not be clarified and these patients is called idiopathic recurrent acute pancreatitis (IRAP).

Endoscopic retrograde cholangiopancreatography (ERCP) is an important minimally invasive treatment for pancreatic diseases. However, the role of ERCP in IRAP patients with normal biliary and pancreatic anatomy remains controversial and there is a lack of high-quality clinical research evidence on endoscopic treatment of IRAP. In a small sample size (N=34) open-label randomized controlled study, IRAP patients were assigned to the experimental group with pancreatic duct stent placement and the control group with selective pancreatograms but no stent. This study demonstrated that stent placement was able to reduce the recurrence rate of AP (53% vs 11%, P \< 0.02). Coté et al performed an open-label randomized trial (N=89) of ERCP with sphincter of Oddi manometry for IRAP patients. Among patients with pancreatic sphincter dysfunction, they found that biliary sphincterotomy and combination of biliary and pancreatic sphincterotomy have similar effects in preventing recurrence of AP, and there was also no significant difference between biliary sphincterotomy and sham surgery in patients with normal sphincter of Oddi manometry. However, some retrospective studies had shown that sphincterotomy works to reduce the recurrence rate of acute pancreatitis.

Currently, there is a shortage of high-quality evidence, and the wide variation in different study designs has led to controversial conclusions. Given the long-standing controversy, we propose to conduct a randomized controlled trial to investigate the efficacy of ERCP in the diagnosis and treatment of Idiopathic recurrent acute pancreatitis.
PURPOSE: A method for synthesizing ivabradine, an addition salt thereof with a pharmaceutically acceptable acid, and a hydride thereof, and a drug are provided to prevent or treat various diseases and heart failure. CONSTITUTION: A method for synthesizing ivabradine of chemical formula I comprises a step of amination of a compound of chemical formula V with amine of chemical formula VI without a solvent or in an alcoholic solvent at 15-100 deg. C under the presence of formic acid and triethyl amine. The amination is performed without the solvent. The amount of the formic acid is 2-50 equivalents per aldehyde. The amount of triethyl amine is 2-50 equivalents per aldehyde.
There were 200 patients aged 65 years and older in the clinical trial for healing and maintenance of healed erosive esophagitis [see Clinical Studies (14.1)]. Of the total number of vonoprazan-treated patients, there were 93 (18%) patients aged 65 years of age and older and 10 (2%) patients aged 75 years of age and older.

There were 139 patients aged 65 years and older in the clinical trial for the relief of heartburn associated with non-erosive gastroesophageal reflux disease [see Clinical Studies (14.3)]. Of the total number of vonoprazan-treated patients, there were 93 (18%) patients aged 65 years of age and older and 14 (3%) patients aged 75 years of age and older. 

There were 218 patients aged 65 years and older in the clinical trial for the treatment of H. pylori infection [see Clinical Studies (14.4)]. Of the total number of vonoprazan-treated patients, there were 153 (22%) patients aged 65 years of age and older and 18 (3%) patients aged 75 years of age and older.

No overall differences in safety or effectiveness were observed between these patients and younger adult patients, and other reported clinical experience has not identified differences in responses between the geriatric and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.

No clinically meaningful differences in the pharmacokinetics of vonoprazan are predicted in patients 65 years of age and older compared to younger adult patients [see Clinical Pharmacology (12.3)].
This study will employ a series of individual N-of-1 trials comparing a high fat, low carbohydrate diet (HF-LC) to a low fat, high carbohydrate diet (LF-HC). Participants will enter the study on a usual diet and will have a 6-day run in period for diet planning and baseline data collection before beginning their intervention. The HF-LC or the LF-HC will be randomized as the starting intervention followed by a wash-out period lasting for 6 days with normal diet between two interventions to eliminate previous intervention effects. Then the participants will be provided with the other diet. Both HF-LC and LF-HC last for 6 days in each set which consists of two wash-out periods and two intervention periods. There will be 3 sets in this study and investigators will aggregate the results of the completed N-of-1 trials across all participants to estimate the group level impacts of HF-LC compared to LF-HC.
<P>PROBLEM TO BE SOLVED: To provide a two agent type foamy hair dyestuff without making the reaction of an oxidative dyestuff too quick on mixing a first agent and a second agent, suppressing the elevation of liquid temperature of the mixed liquid, even though containing the oxidative dyestuff in a large concentration, and also capable of performing the dyeing without having color unevenness.  <P>SOLUTION: This two agent type foamy hair dyestuff comprising a first agent containing an alkaline agent, a second agent containing hydrogen peroxide and a non-aerosol foamer container for ejecting the mixed liquid of the first and second agents as foamy state is provided by containing components (A), (B) and (C) in the mixed liquid and having the 1 to 300 mPa s viscosity of the mixed liquid at 25°C. (A) A 1.06 to 6.0 mass% oxidative dyestuff. (B) Ammonia. (C) A 0.8 to 1.8 mass% carbonate ion or bicarbonate ion.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The diene derivs. of formula (I) are prepared by reacting the reactive deriv. of carboxylic acid of formula (II) with the amine deriv. of formula (III) and reducing the amido derivs of the product.  In formulas, R1, R2, R3 and R4 are each H, hydroxyl or lower alkyl; X is H or halogen.  The diene derivs. of formula (I) are useful as vasodilators.
The referral of patients with indication to PICC-line implantation at the institute of diagnostic and interventional radiology occurs through different departments of the University Hospital Jena. The patients are registered for radiological treatment and checked again by a radiologist if a PICC-line implantation is indicated. If this is the case, the radiologist conducts an informed consent discussion with the patient about possible complications and risks during intervention and informs him also about a possible study participation. After signature of the written informed consent, the patient is included. He can, at any time, withdraw his consent. On the intervention day, the patient is randomly assigned to one of the two study arms through envelope (145 cm vs 70 cm). The intervention time is documented. After intervention, the patient is transferred back to the ward or sent home. The examination of the puncture site before discharge is performed by a ward physician or by the family doctor.

Within 2 weeks after PICC-line implantation, the treating physician is contacted and questioned about possible complications (catheter occlusion, haematoma, infection of the puncture site, arm vein thrombosis, pain, etc.), that are then thoroughly documented.
Extract of Ajuga turkestanica is used as a cosmetic treatment to prevent sign of aging.  The extract is characterized by containing at least one ecdysteroid and at least one iridoid, and is obtainable by extraction of at least part of the plant using a solvent or mixture of solvents that contains 0 - 60 % water, together with a 1-4C alcohol, and/or acetone, and/or butylene glycol, and/or propylene glycol. The plant is of the Labiae family and is found in central Asia, especially in Uzbekistan. Extraction is preferably effected on the whole plant under reflux for 1 - 4 hours. The preferred extracting solvent mixtures are 80 % ethanol or methanol/ 20 % water, 80 % acetone/20 % water, 50 % propylene or butylene glycol/50 % water. The extract preferably contains 1 part of ecdysteroid, such as ecdysterone, ecdysterone 2,3-monoacetonide, turkesterone, cyasterone, 22-acetyl cyasterone or  alpha - ecdysone, and 2-4 parts of at least one iridoid, especially harpagide or its 8-O-acetylated derivative.
Effects on Electrocardiogram

A thorough QT trial has been conducted for dolutegravir. Neither the effects of abacavir nor lamivudine as single entities or the combination of abacavir, dolutegravir, and lamivudine on the QT interval have been evaluated.

In a randomized, placebo-controlled, cross-over trial, 42 healthy subjects received single-dose oral administrations of placebo, dolutegravir 250‑mg suspension (exposures approximately 3–fold of the 50-mg once-daily dose at steady state), and moxifloxacin 400 mg (active control) in random sequence. After baseline and placebo adjustment, the maximum mean QTc change based on Fridericia correction method (QTcF) for dolutegravir was 2.4 msec (1-sided 95% upper CI: 4.9 msec). Dolutegravir did not prolong the QTc interval over 24 hours postdose.

Effects on Renal Function

The effect of dolutegravir on renal function was evaluated in an open-label, randomized, 3-arm, parallel, placebo-controlled trial in healthy subjects (n = 37) who received dolutegravir 50 mg once daily (n = 12), dolutegravir 50 mg twice daily (n = 13), or placebo once daily (n = 12) for 14 days. A decrease in creatinine clearance, as determined by 24-hour urine collection, was observed with both doses of dolutegravir after 14 days of treatment in subjects who received 50 mg once daily (9% decrease) and 50 mg twice daily (13% decrease). Neither dose of dolutegravir had a significant effect on the actual glomerular filtration rate (determined by the clearance of probe drug, iohexol) or effective renal plasma flow (determined by the clearance of probe drug, para-amino hippurate) compared with the placebo.